Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 17/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941939 | 0.81 | GRM2 (0.57) | GRM2 | |
| SCHEMBL8942117 | 0.80 | GRM2 (0.56) | GRM2 | |
| SCHEMBL6801533 | 0.80 | GRM2 (0.56) | GRM2 | |
| SCHEMBL2789355 | 0.80 | GRM2 (0.60) | GRM2 | |
| SCHEMBL9236212 | 0.80 | GRM2 (0.60) | GRM2 | |
| SCHEMBL9242572 | 0.80 | GRM2 (0.51) | GRM2MAPK1L3MBTL1 | |
| SCHEMBL2786197 | 0.79 | GRM2 (0.55) | GRM2 | |
| SCHEMBL8941844 | 0.79 | GRM2 (0.57) | GRM2 | |
| SCHEMBL8941850 | 0.78 | GRM2 (0.55) | GRM2 | |
| SCHEMBL8941876 | 0.76 | GRM2 (0.58) | GRM2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552055-B2 | Peroxidsome proliferator activated receptors | DANA-FARBER CANCER INSTITUTE | 2003-04-22 | — | — | US | claimed |
| US-20020106796-A1 | PAX8-PPARgamma nucleic acid molecules and polypeptides and uses thereof | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2002-08-08 | — | — | US | claimed |
| WO-2001052789-A2 | PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-20110300129-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010075037-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7635708-B2 | Methods and pharmaceutical compositions for inhibiting tumor cell growth | DANA-FARBER CANCER INSTITUTE (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060019910-A1 | Methods for treating and preventing insulin resistance and related disorders | GREENBERG ANDREW S | 2006-01-26 | — | — | US | disclosed |
| US-20050148536-A1 | Methods for treating and preventing insulin resistance and related disorders | GREENBERG ANDREW S (US) | 2005-07-07 | — | — | US | disclosed |
| US-20040171533-A1 | Methods and compositions for regulating adiopocytes | CURIS, INC. | 2004-09-02 | — | — | US | disclosed |
| EP-1410799-A1 | Methods and pharmaceutical compositions for inhibiting tumour cell growth | DANA-FARBER CANCER INSTITUTE (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6723506-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE TREATMENT OF TUMORS | BRIGHAM AND WOMEN'S HOSPITAL | 2004-04-20 | — | — | US | disclosed |
| US-20020006950-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOR CELL GROWTH | DANA-FARBER CANCER INSTITUTE | 2002-01-17 | — | — | US | disclosed |
| WO-2001064238-A2 | METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES | CURIS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001052789-A2 | PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6242196-B1 | INHIBITING PROLIFERATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS-GAMMA RESPONSE HYPERPROLIFERATIVE CELL BY CONTACTING WITH AGONIST AND MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR | DANA-FARBER CANCER INSTITUTE | 2001-06-05 | — | — | US | disclosed |
| EP-0948324-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998025598-A9 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH | — | 1998-11-26 | — | — | WO | disclosed |
| WO-1998025598-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH | DANA-FARBER CANCER INSTITUTE (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5521202-A | ANTIDIABETIC AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| EP-0645387-A1 | THIAZOLIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171533-A1 | Methods and compositions for regulating adiopocytes | FABP4, APMAP, ADIPOR1 | GRM2 2744/4885DRD4 4521/4885MAPK1 4375/4885 |
| US-20020006950-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOR CELL GROWTH | PPARD, PPARG, PPARA | GRM2 2637/4885DRD4 2710/4885MAPK1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.